EMA, FDA and TGA joint GMP inspection programme

Home/Guidelines | Posted 13/05/2011

On 27 April 2011, the FDA announced that it is working with the EMA and Australia’s Therapeutic Goods Administration (TGA) to finalise a permanent pilot programme for joint good manufacturing practice (GMP) inspections at active pharmaceutical ingredient (API) manufacturing facilities.

FDA and EMA to join forces on quality

Home/Guidelines | Posted 29/04/2011

EMA and FDA have launched on 1 April 2011 a three-year pilot programme to allow parallel evaluation of quality elements, known as Quality by Design (QbD), of selected applications submitted to both agencies at the same time.

China’s regulatory authority adopt CTD format for NDAs

Home/Guidelines | Posted 25/03/2011

On 25 September 2010, China’s State Food and Drug Administration (SFDA) issued new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.

EMA adopts guideline on biosimilar monoclonal antibodies

Home/Guidelines | Posted 11/02/2011

EMA announced on its website that it has adopted the long-anticipated guideline on biosimilar monoclonal antibodies.

India regulatory authority to adopt CTD format for NDAs

Home/Guidelines | Posted 11/02/2011

On 28 October 2010, India’s Central Drugs Standard Control Organization (CDSCO) released new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.

The FDA’s 2010 final rule and draft guidance

Home/Guidelines | Posted 04/02/2011

In an effort to improve safety detection, the FDA issued a final rule and draft guidance on 29 September 2010 to clarify the requirements governing safety reporting requirements for human drug and biological products subject to an investigational new drug (IND) application.

EGA meeting London 2010: monoclonal antibodies and biosimilars guidelines

Home/Guidelines | Posted 10/09/2010

In his opening address to the 8th EGA International Symposium on Biosimilar Medicines held in London on 2–3 September 2010, EGA Director General Mr Greg Perry praised the EU for inspiring the rest of the world regarding development of biosimilar guidelines.

The current EU regulatory framework governing biosimilars

Home/Guidelines | Posted 25/08/2010

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has guidelines that provide a framework for the development of ‘biosimilars’ in the EU. The recent licensing of recombinant somatropins and several erythropoietins has proved that the present system works. Can the same regulatory path also be applied to more complex biologicals, such as monoclonal antibodies (mAbs)?

FDA Form 483 – punishment or learning opportunity?

Home/Guidelines | Posted 10/08/2010

The US FDA is authorised to perform inspections under the Federal Food, Drug, and Cosmetic Act. The FDA Form 483 is a form used by the FDA to document and communicate concerns discovered during these inspections and to list items that deviate from Good Manufacturing Practices.

Licensing of biosimilars in Europe

Home/Guidelines | Posted 02/07/2010

How is licensing of biosimilars actually being applied in Europe? This was the question broached in a paper by Dr Christian Schneider – Chairman of both the Committee for Advanced Therapies and Biosimilar Medicinal Products Working Party and Co-opted member of the Committee for Medicinal Products for Human Use (CHMP).